Literature DB >> 12496409

IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice.

Vincenzo Bronte1, Paolo Serafini, Carmela De Santo, Ilaria Marigo, Valeria Tosello, Alessandra Mazzoni, David M Segal, Caroline Staib, Marianne Lowel, Gerd Sutter, Mario P Colombo, Paola Zanovello.   

Abstract

We previously demonstrated that a specialized subset of immature myeloid cells migrate to lymphoid organs as a result of tumor growth or immune stress, where they suppress B and T cell responses to Ags. Although NO was required for suppression of mitogen activation of T cells by myeloid suppressor cells (MSC), it was not required for suppression of allogenic responses. In this study, we describe a novel mechanism used by MSC to block T cell proliferation and CTL generation in response to alloantigen, which is mediated by the enzyme arginase 1 (Arg1). We show that Arg1 increases superoxide production in myeloid cells through a pathway that likely utilizes the reductase domain of inducible NO synthase (iNOS), and that superoxide is required for Arg1-dependent suppression of T cell function. Arg1 is induced by IL-4 in freshly isolated MSC or cloned MSC lines, and is therefore up-regulated by activated Th2, but not Th1, cells. In contrast, iNOS is induced by IFN-gamma and Th1 cells. Because Arg1 and iNOS share L-arginine as a common substrate, our results indicate that L-arginine metabolism in myeloid cells is a potential target for selective intervention in reversing myeloid-induced dysfunction in tumor-bearing hosts.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12496409     DOI: 10.4049/jimmunol.170.1.270

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  182 in total

Review 1.  Myeloid-derived suppressor cells in transplantation and cancer.

Authors:  Jordi C Ochando; Shu Hsia Chen
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

2.  Adjuvant immunotherapy of experimental autoimmune encephalomyelitis: immature myeloid cells expressing CXCL10 and CXCL16 attract CXCR3+CXCR6+ and myelin-specific T cells to the draining lymph nodes rather than the central nervous system.

Authors:  Richard A O'Connor; Xujian Li; Seth Blumerman; Stephen M Anderton; Randolph J Noelle; Dyana K Dalton
Journal:  J Immunol       Date:  2012-01-27       Impact factor: 5.422

Review 3.  Modulation of antitumor responses by dendritic cells.

Authors:  Johannes Vieweg; Andrew Jackson
Journal:  Springer Semin Immunopathol       Date:  2005-01

4.  Polyamine-blocking therapy reverses immunosuppression in the tumor microenvironment.

Authors:  Candace S Hayes; Allyson C Shicora; Martin P Keough; Adam E Snook; Mark R Burns; Susan K Gilmour
Journal:  Cancer Immunol Res       Date:  2013-10-07       Impact factor: 11.151

5.  Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator.

Authors:  Prashant Trikha; Robert L Plews; Andrew Stiff; Shalini Gautam; Vincent Hsu; David Abood; Robert Wesolowski; Ian Landi; Xiaokui Mo; John Phay; Ching-Shih Chen; John Byrd; Michael Caligiuri; Susheela Tridandapani; William Carson
Journal:  Oncoimmunology       Date:  2016-07-25       Impact factor: 8.110

6.  Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination.

Authors:  Carmela De Santo; Paolo Serafini; Ilaria Marigo; Luigi Dolcetti; Manlio Bolla; Piero Del Soldato; Cecilia Melani; Cristiana Guiducci; Mario P Colombo; Manuela Iezzi; Piero Musiani; Paola Zanovello; Vincenzo Bronte
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

Review 7.  Altered macrophage differentiation and immune dysfunction in tumor development.

Authors:  Antonio Sica; Vincenzo Bronte
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 8.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

9.  Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism.

Authors:  Lyse A Norian; Paulo C Rodriguez; Leigh A O'Mara; Jovanny Zabaleta; Augusto C Ochoa; Marina Cella; Paul M Allen
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

10.  Inducible Nitric Oxide Synthase and CD11b+Gr1+ Cells Impair Lymphatic Contraction of Tumor-Draining Lymphatic Vessels.

Authors:  Shan Liao; Echoe M Bouta; Linda M Morris; Dennis Jones; Rakesh K Jain; Timothy P Padera
Journal:  Lymphat Res Biol       Date:  2018-10-24       Impact factor: 2.589

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.